Abstract:BACKGROUND Postmenstrual spotting and chronic pelvic pain after cesarean delivery (CD) are associated with the presence of niches. Levonorgestrel intrauterine system (LNG-IUS 52 mg) and hysteroscopic niche resection have been shown to relieve niche-related symptoms six months after the intervention. OBJECTIVE This trial aimed to compare the effectiveness of LNG-IUS 52 mg with hysteroscopic niche resection in reducing niche-related postmenstrual spotting. STUDY DESIGN This randomized, open-label, controlled trial was conducted at a medical center in Shanghai, China. Women with symptoms of postmenstrual spotting after CD, with a niche depth of at least 2 mm and residual myometrium of at least 2.2 mm on magnetic resonance imaging (MRI), and no intention to conceive within the next year were randomly assigned to receive treatment with LNG-IUS 52 mg or hysteroscopic niche resection. The primary outcome was the reduction in postmenstrual spotting 6 months after randomization, defined as the percentage of women with a reduction of at least 50% in spotting days from baseline. Efficacy and safety were assessed using intention-to-treat analysis. RESULTS Between September 2019 and January 2022, 208 women were randomized into the LNG-IUS group (N=104) or the hysteroscopic niche resection group (N=104). At the 6 th month follow-up, a 50% reduction in spotting had occurred in 78.4% (80/102) of women in the LNG-IUS group and in 73.1% (76/104) of women in the hysteroscopic niche resection group (RR=1.07, [95%CI 0.92-1.25]; P=0.370). Spotting decreased over time (P trend =0.001), with a stronger reduction being observed in the LNG-IUS group (P=0.001). There was also a significant interaction between time and treatment (P=0.007). From nine months onwards, a more significant reduction in spotting was observed in the LNG-IUS group than in the hysteroscopic niche resection group (9 th month 89.2% vs. 72.1%, RR=1.24, [95% CI 1.08-1.42]; 12 th month 90.2% vs. 70.2%, RR=1.29, [95% CI 1.12-1.48]). Moreover, compared with the hysteroscopic niche resection group, the LNG-IUS group had significantly fewer postmenstrual spotting days and total bleeding days from six months onwards (all P <0.001) as well as less pelvic pain from three months onwards (all P <0.010). No intervention-related complications were reported in any group. During follow-up, 11 (10.8%) women reported hormone-related side-effects and two women (2.0%) in the LNG-IUS group had spontaneous partial expulsion. Meanwhile, three unintended pregnancies were reported in the hysteroscopic niche resection group. CONCLUSION In women with niche-related postmenstrual spotting, LNG-IUS was not more effective than hysteroscopic niche resection in reducing the number of spotting days by at least 50% at 6 months. However, the LNG-IUS was superior in reducing spotting from 9 months onwards, as it reduced the absolute number of spotting days from six months onwards and pelvic pain from three months onwards.

Bleeding Pattern Difference Between Levonorgestrel Intrauterine System and Copper Intrauterine Devices Inserted Immediately Post-Abortion: a Multicenter, Prospective, Observational Cohort Study in Chinese Women.

Levonorgestrel-releasing Intrauterine System Effects on Metabolic Variables in PCOS.

Postplacental Insertion of Levonorgestrel Intrauterine System Versus Copper Intrauterine Device: A Prospective Study

[Efficacy and Safety of Low-Dose Levonorgestrel-Releasing Intrauterine System in Chinese Women: a Multicenter, Single-Arm, Open Labeled Interventional Trial].

[A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia]

Is there a difference in the clinical profile and outcome of women using levonorgestrel IUD for abnormal uterine bleeding and those using it for contraception?: A comparative cross-sectional study

[Clinic Observation of a Levonorgestrel-Releasing Intrauterine System Inserted Immediately after Artificial Abortion].

Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system

Uterine volume, menstrual patterns, and contraceptive outcomes in users of the levonorgestrel-releasing intrauterine system: A cohort study with a five-year follow-up

Effectiveness of Levonorgestrel Releasing Intrauterine System in Perimenopausal Women with Heavy Menstrual Bleeding: A Prospective Study at a Teaching Hospital in India

[Changes of menstruation patterns and adverse effects during the treatment of LNG-IUS for symptomatic adenomyosis]

Levonorgestrel-releasing intrauterine device to treat abnormal uterine bleeding; not one treatment option fits all

The Effect of the Levonorgestrel-Releasing Intrauterine System on Myometrial Blood Flow in Patients With Heavy Menstrual Bleeding

Preliminary report on the use of a levonorgestrel intrauterine system for the treatment of intermenstrual bleeding due to previous cesarean delivery scar defect

Efficacy of Levonorgestrel Intrauterine System in the Management of Abnormal Uterine Bleeding: A Retrospective Analysis of a 100 Women

Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome

Levonorgestrel-releasing intrauterine system vs. systemic medication or blank control for women with dysmenorrhea: Systematic review and meta-analysis of randomized controlled trials

Utility of the Levonorgestrel-Releasing Intrauterine System in the Treatment of Abnormal Uterine Bleeding and Dysmenorrhea: A Narrative Review.

Does Timing of Levonorgestrel Insertion in Women with Abnormal Uterine Bleeding Affect its Expulsion and Bleeding Pattern? A Follow-Up Study

Comparing levonorgestrel intrauterine system versus hysteroscopic niche resection in women with postmenstrual spotting related to a niche in the uterine cesarean scar: a randomized, open label, controlled trial

Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity